What changed
$EMR — Industrial automation and technology solutions provider.
🎯 Q1 FY26 | Rev $5B | EPS $1.54 vs $1.53 🟢
💡 Consensus expects steady industrial growth and margin expansion. The Q1 beat was modest (0.44% on EPS) and revenue growth was only 2.9% YoY. The market may be pricing in a stronger recovery in discrete automation than is likely given mixed end-market signals (e.g., Control & Software -2% underlying).
🏢 Business Quality: 7/10 | Valuation: fair
📉 Reward/Risk: Upside 8% to $148 (22x FY26 EPS of $6.50) vs downside 12% to $121 (18.5x if organic growth disappoints). Ratio ~0.67:1, unfavorable for active long.
🔮 Catalyst: Q2 FY26 earnings (expected early May 2026). Key metric: underlying sales growth, especially in Control Systems & Software (must improve from -2% to positive). Failure signal: further deceleration in discrete automation orders.
Also in play: $HCA $UHS $THC $CYH $DVA $CERN